Literature DB >> 8104726

Pharmacodynamics of vecuronium in patients with and without renal failure: a meta-analysis.

C Beauvoir1, P Peray, J P Daures, J L Peschaud, F D'Athis.   

Abstract

Eight trials comparing the effects of vecuronium in patients with either normal renal function or renal failure were subjected to a meta-analysis. Vecuronium doses were similar in the different trials, identical in the two patient groups of any given trial, and ranged from 0.05 to 0.14 mg.kg-1. Neuromuscular blockade was assessed by TOF or single twitch stimulation, and recorded by either mechanomyography or electromyography. Indices of blockade included onset time (from injection to maximal twitch depression), duration of action (from injection to recovery to 25% of control twitch) and 25-75% recovery index. Statistical analysis used Hedges method: effect size and variance were calculated for each relevant outcome, then the global effect size was estimated by pooling the effect sizes of each trial. Three separate meta-analyses were conducted. No differences were found either in onset time, or in recovery index between the two groups, whereas the duration of action was longer in the renal failure group. It is concluded that renal function is likely involved in the pharmacokinetic parameters of vecuronium.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8104726     DOI: 10.1007/BF03009763

Source DB:  PubMed          Journal:  Can J Anaesth        ISSN: 0832-610X            Impact factor:   5.063


  30 in total

Review 1.  [Meta-analysis of clinical trials].

Authors:  J P Pignon; T Poynard
Journal:  Gastroenterol Clin Biol       Date:  1991

2.  Adjuvant chemotherapy for breast cancer. A pooled estimate based on published randomized control trials.

Authors:  H N Himel; A Liberati; R D Gelber; T C Chalmers
Journal:  JAMA       Date:  1986-09-05       Impact factor: 56.272

3.  Meta-analysis of the effects of educational and psychosocial interventions on management of diabetes mellitus.

Authors:  D Padgett; E Mumford; M Hynes; R Carter
Journal:  J Clin Epidemiol       Date:  1988       Impact factor: 6.437

4.  Clinical recovery and train-of-four ratio measured mechanically and electromyographically following atracurium.

Authors:  J Engbaek; D Ostergaard; J Viby-Mogensen; L T Skovgaard
Journal:  Anesthesiology       Date:  1989-09       Impact factor: 7.892

Review 5.  [Meta-analysis on randomized trials comparing the results of low-molecular weight heparins to those of fractioned heparins in the prevention of deep venous thrombosis].

Authors:  J P Daures; J F Schved; I Momas; J C Gril; P Azoulay; F Gremy
Journal:  Rev Epidemiol Sante Publique       Date:  1989       Impact factor: 1.019

6.  Disposition and urinary excretion of vecuronium bromide in anesthetized patients with normal renal function or renal failure.

Authors:  A F Bencini; A H Scaf; Y J Sohn; C Meistelman; A Lienhart; U W Kersten; S Schwarz; S Agoston
Journal:  Anesth Analg       Date:  1986-03       Impact factor: 5.108

7.  Pharmacokinetics of Org NC45 (norcuron) in patients with and without renal failure.

Authors:  M R Fahey; R B Morris; R D Miller; T L Nguyen; R A Upton
Journal:  Br J Anaesth       Date:  1981-10       Impact factor: 9.166

8.  Atracurium, vecuronium and pancuronium in end-stage renal failure. Dose-response properties and interactions with azathioprine.

Authors:  L Gramstad
Journal:  Br J Anaesth       Date:  1987-08       Impact factor: 9.166

9.  Vecuronium in patients with and without renal failure.

Authors:  R Orko; A Heino; P H Rosenberg
Journal:  Acta Anaesthesiol Scand       Date:  1985-04       Impact factor: 2.105

10.  Pharmacology of vecuronium in patients with end-stage renal failure.

Authors:  C Meistelman; A Lienhart; C Leveque; M O Bitker; B Pigot; P Viars
Journal:  Eur J Anaesthesiol       Date:  1986-03       Impact factor: 4.330

View more
  3 in total

1.  Early neuromuscular recovery characteristics following administration of mivacurium plus vecuronium.

Authors:  R G Stout; S J Brull; D Kelly; D G Silverman
Journal:  Can J Anaesth       Date:  1996-04       Impact factor: 5.063

Review 2.  Selecting neuromuscular-blocking drugs for elderly patients.

Authors:  Tristan M Cope; Jennifer M Hunter
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

3.  Secondary hyperparathyroidism shortens the action of vecuronium in patients with chronic renal failure.

Authors:  K Takita; Y Goda; O Kemmotsu; H Mashio; A Okuyama; Y Ito; H Sakamoto; H Kawahigashi
Journal:  Can J Anaesth       Date:  1995-05       Impact factor: 5.063

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.